Genelux (GNLX) stock

Viral immunotherapies , market cap $82.3M

Makes viral immunotherapies for cancer

Worth $82.3M

Pre-market

$2.09

+6.63%

Close $1.96 +7.69%

As of 9:05 AM ET pre-market, delayed 15+ min · Live for Pro members

Why GNLX fell on Oct 21

Down 17% on Oct 21, and still 22% under its Oct 20 close.

Genelux fell 17% that day while pharma stocks fell a median 0.5%: it trailed its group by 17 points.

No SEC filing or news in our sources explains it.

Sources: Price history, Oct 21, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time GNLX moves

Free account, no card. An optional alert when GNLX moves or its score changes.

Or see it live, free until tomorrow morning. No account.

1 more reason, free with an account →How the business stands, the timeline, and its peers, for Pro members.

Quality Score

-10

Poor

In its industry

#89of 90

Pharma

Checks firing

2of 14

Transition

From 52-week high

-73.9%

under its best in a year

GNLX's Quality Score rose 1 point on Fri, Nov 6, to -10. It closed near its high of the day (2 chart checks started).

Follow GNLX's trial news. Pro members can get an alert when Genelux files news, and see its trials, share raises, and its CEO's filings.

Get an alert when GNLX files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Cash$18.7M, about 3 quarters at the last year's spendingOn Jun 30

Key facts on GNLX

Key facts on GNLX
Since its Jun 2023 high	Down 95% a $5.2M loss → a $32.1M loss a year
Latest filing	10-Q, Aug 13 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind GNLX's -10, free with an account →5 more reasons behind GNLX's -10, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$18.7M, about 3 quarters at the last year's spendingOn Jun 30

GNLX catalysts

Coming up

What's next for GNLX, and how long its cash lasts

Its trials

A trial underway: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)Phase 3 · Recruiting · 186 people · main data estimated Dec 2026 · NCT05281471

1 more trial, 22 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 3 quarters

$18.7M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Feb 2, 2024)
At-the-market share sales program (424B5, filed Mar 19, 2026)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

Chief Technical Officer Joseph Cappello sold 668 shares on Nov 3. 20 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Thomas Zindrick buys or sells

For Pro members: every trade, and Thomas Zindrick’s 14 filings and quotes.

Get an alert when GNLX files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How GNLX ranks in Pharma

GNLX is #89 of 90 by Quality Score.

How GNLX ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	8/14	24
2	LLYEli Lilly	5/14	18
3	CRONCronos	5/14	18
	GLASGlass House Brands		Open for its score
	GMABGenmab		Open for its score
	GRFSGrifois		Open for its score
	GSKGSK		Open for its score
89	GNLXGenelux	2/14	-10

GNLX sales and profit by year

Sales and profit by year

Sales fell every year from 2022 to 2025, to $8K. It lost money in each of the four years.

GNLX has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on GNLX, and all 14 on every stock.Get in free →

GNLX RSI on Nov 6: 40.3, below its 50-day and 200-day averages

Not scored

RSI 40.3, MACD below signal, below both averages. Not scored.13 readings

The deep dive on GNLX

What it does and how it makes money2 findingsAn operating loss of $33.2M in fiscal 2025, on $8K of sales.Annual report, filed Mar 19, 2026
Where it stands1 findingFor Pro members1 finding on where GNLX stands: its cash, debt, and share count, for Pro members
What changed in its filings1 findingFor Pro members1 finding from GNLX’s filings, for Pro members
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades GNLX, for Pro members

5 more findings on GNLX, each with its source, for Pro members.

GNLX share count over time

18% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of GNLX outstanding, as filed
Shares outstanding	As of
45.2M	Aug 11, 2026
44.8M	May 3, 2026
44.8M	Mar 16, 2026
38.1M	Oct 30, 2025

Offerings, shelves, and splits of GNLX, from its filings
From its filings	Filed
Set up an at-the-market program for up to $100M of shares, about 121% of its market value	Mar 19, 2026
Raised $20M in a sale of shares, about 24% of its market value	Jan 8, 2026
Raised $10.5M in a sale of shares, about 13% of its market value	Mar 25, 2025
Registered shares for a later sale (S-3)	Feb 2, 2024

GNLX insider trades

5 insiders sold $204K across 11 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellThomas Zindrick$6KPresident and CEOat $2.05 on Nov 3, filed Nov 5

SellThomas ZindrickPresident and CEO$6Kat $2.05 on Nov 3, filed Nov 5

All 11 insider filings on GNLX from the last six months, for Pro members.

All GNLX insider trades

GNLX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Thomas ZindrickPresident and CEO · 3 trades
Joseph CappelloChief Technical Officer · 3 trades
Yong YuChief Scientific Officer · 3 trades
Ralph SmallingHead of Regulatory · 1 trade
John W. SmitherDirector · 1 trade

See insider trades by person

Which ETFs hold GNLX?

In ETFs: GNLX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Genelux

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

26 employeesWestlake Village, CAgenelux.com

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on GNLX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn GNLX's score around: 8 things
5 more filings explained, a plain line each
6 more things pulling GNLX's score down

BreakawayNov 5Thomas Zindrick sold GNLX$6K at $2.05, filed Nov 5

Alerts are optional.

See GNLX's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: GNLX's Quality Score is -10 (Poor), #89 of 90 in Pharma. Insiders sold $204K in the last 6 months (Form 4).

What does GNLX's Quality Score say?

GNLX scores -10 today, which Breakaway calls Poor. It is #89 of 90 in Pharma by Quality Score, with 2 of 14 chart checks firing. Down 17% on Oct 21, and still 22% under its Oct 20 close. Cash lasts about 3 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is GNLX's Quality Score?

GNLX scores -10 today, which Breakaway calls Poor (below zero). That is #89 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GNLX's -10.

Are insiders buying GNLX?

5 insiders sold $204K across 11 filings in the last 6 months. No open-⁠market buys on record. The newest is Thomas Zindrick, President and CEO, who sold $6K on Nov 3. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.